Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation

Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation

For locally advanced (T3-4/N+M0) rectal cancer (LARC), neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) is the standard treatment. It was demonstrated to decrease the local recurrence rate and increase the tumor response grade. However, the distant metastasis remains...

Full description

Bibliographic Details
Main Authors: Yaqi Wang, Lijun Shen, Juefeng Wan, Hui Zhang, Ruiyan Wu, Jingwen Wang, Yan Wang, Ye Xu, Sanjun Cai, Zhen Zhang, Fan Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
locally advanced rectal cancer
neoadjuvant chemoradiotherapy
immunotherapy
tumor response
anus preservation
research progress
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1067036/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1067036/full

Similar Items